1441390-17-5|Lanopepden Mesylate|N-((R)-2-(Cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazineyl)-3-oxopropyl)-N-hydroxyformamide Mesylate|-范德生物科技公司

Lanopepden Mesylate

NMR下载 COA and HPLC MSDS下载
names：
N-((R)-2-(Cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazineyl)-3-oxopropyl)-N-hydroxyformamide Mesylate
CAS号：
1441390-17-5
MDL Number：
MF(分子式)： C23H38FN7O7S MW(分子量)： 575.6574
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Lanopepden Mesylate
英文别名	GSK-1322322A; GSK 1322322A; GSK1322322A; GSK-322A; GSK 322A; GSK322A
CAS号	1441390-17-5
SMILES	O=CN(C[C@@H](CC1CCCC1)C(NNC2=NC(C)=NC(N3C[C@@]4([H])COCCN4CC3)=C2F)=O)O.OS(=O)(C)=O
Inchi	InChI=1S/C22H34FN7O4.CH4O3S/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16;1-5(2,3)4/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26);1H3,(H,2,3,4)/t17-,18+;/m1./s1
InchiKey	UNGNACZMQRGYNV-URBRKQAFSA-N
分子式 Formula	C23H38FN7O7S
分子量 Molecular Weight	575.6574
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Lanopepden Mesylate(CAS:1441390-17-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Lanopepden Mesylate is a novel peptide deformylase inhibitor against streptococcus pneumoniae, haemophilus influenzae, and staphylococcus aureus
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Maral S, Bakanay SM, Kucuksahin O, Dilek I. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib. J Oncol Pharm Pract. 2019 Jul 30:1078155219863469. doi: 10.1177/1078155219863469. [Epub ahead of print] PubMed PMID: 31359838.

[2]Li G, Chan YL, Sukjamnong S, Anwer AG, Vindin H, Padula M, Zakarya R, George J, Oliver BG, Saad S, Chen H. A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. Nutrients. 2019 Jul 21;11(7). pii: E1669. doi: 10.3390/nu11071669. PubMed PMID: 31330878.

[3] Lind J, Czernilofsky F, Vallet S, Podar K. Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opin Emerg Drugs. 2019 Jul 29:1-20. doi: 10.1080/14728214.2019.1647165. [Epub ahead of print] PubMed PMID: 31327278.

[4] Hung KD, Van QL, Hoang GN, Bich PNT. Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam. Cancer Control. 2019 Jan-Dec;26(1):1073274819863776. doi: 10.1177/1073274819863776. PubMed PMID: 31319677.

[5] Lunge S, Bhise R. Imatinib Mesylate Induced Erythroderma. J Assoc Physicians India. 2018 Dec;66(12):79-80. PubMed PMID: 31313559.

6: Wejih DM, Leila GE, Ali CM, Ramzi N, Ibtissem B, Chadli D. Rectal stromal tumor with an exceptional liver and bone metastatic locations. Pan Afr Med J. 2019 Mar 20;3

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开